By Victor Swezey


Eli Lilly is working with OpenAI to create new antimicrobials that are effective against drug-resistant pathogens.

The Indianapolis-based pharmaceutical company said that it will use the technology company's generative AI capabilities to treat antimicrobial resistance, which it called one of the greatest threats in public health and development.

Antimicrobial resistance occurs when pathogens stop responding to medicines over time, and can result from misuse or overuse of antimicrobials, according to Eli Lilly. The issue affects countries across the world but can be worsened by poverty and inequality.

Eli Lilly's Social Impact Venture Capital Portfolio in 2020 committed $100 million to the AMR Action Fund, with the goal of providing patients with two to four new antibiotics by 2030.


Write to Victor Swezey at victor.swezey@wsj.com


(END) Dow Jones Newswires

06-25-24 1105ET